Our Research Members
Professor, Department of Obstetrics & Gynaecology and Institute of Medical Sciences
Senior Investigator, Lunenfeld-Tanenbaum Research Institute
Tier 1 Canada Research Chair in Stem Cells and Regeneration
Somatic cell reprogramming to induced pluripotent stem cells requires the expression of 2-4 key transcription factors. We have demonstrated that the piggyBac transposon-based transgene delivery system combined with tetracycline inducible gene expression can be used to reprogram cells with a comparably high efficiency to viral transduction, both from mouse and human somatic cells. Unique properties of our transposon-based system form the foundation for exploring the plasticity of the ß-cell. Using a transgenic reprogrammable mouse line, we are exploring the possibility expanding, differentiating and trans-differentiating cells of the pancreatic lineage in a whole organism context and ex vivo. T his research aims to take a giant leap forward in the understanding of the cellular plasticity of ß-cells and the development of novel tools for bringing efficient cell-based therapies to the future of medicine.
Professor, Department of Paediatrics, Division of Haematology/Oncology
Associate Scientist, Hospital for Sick Children Research Institute
Dr. Nathan’s research focuses on long-term outcomes in survivors of childhood cancer. His interests include obesity and other metabolic sequelae of cancer treatment, as well as cardiac outcomes in children treated with cardiotoxic chemotherapy or radiation. In addition, he is interested in health care utilization and screening/surveillance late effects in adult survivors of childhood cancer.
AssociateProfessor, Department of Medicine, Division of Endocrinology & Metabolism; Department of Physiology and Department of Laboratory Medicine and Pathobiology
Scientist, Keenan Research Center, Li Ka Shing Knowledge Institute, St Michael’s Hospital
30 Bond Street, Shuter Wing, 3rd Floor, Room 3-041
Toronto, ON M5B 1W8
My research lab is primarily interested in the area of genetics of lipid disorders and cardio-metabolic disorders with special emphasis on high density lipoprotein (HDL) metabolism. We use transgenic/knock out mice as models and our tools include in vivo experiments, ex vivo and in vitro assays at tissue, cellular, and molecular levels. We are particularly interested in using in vivo mouse models to examine the impact of specific genetic-based dyslipidemic states on atherogenesis, diabetogenesis and more recently, obesity and brown fat development. Detailed analyses of these animal models using cellular, molecular and genetic markers will also be carried out to elucidate the underlying mechanism of such disease processes and their interactions. Such genetic models are also used to study the effects of dietary and drug interventions.
Assistant Professor, Department of Physiology
Harry Rosen Chair in Diabetes and Regenerative Medicine Research, McEwen Centre for Regenerative Medicine
Scientist, Division of Experimental Therapeutics, Toronto General Research Institute, UHN
– Generation of pancreatic beta cells from human pluripotent stem cells
– Cell therapy for type I diabetes
– Modeling lineage commitment and human development in vitro
– Using human pluripotent stem cell-derived pancreatic cells as a platform for drug screening
Assistant Professor, Institute of Biomaterials and Biomedical Engineering
Laboratory of Medicine and Pathobiology
Assistant Scientist, Division of Experimental Therapeutics, Toronto General Research Institute, University Health Network
Member of the Heart & Stroke/Richard Lewar Centre of Excellence (HSRLCE), University of Toronto
Member of Ontario Institute for Regenerative Medicine (OIRM)
101 College St.
Toronto, ON M5G 1L7
We are investigating how diabetes affects vessel formation (angiogenesis and arterio-venous specification) and its implications in tissue engineering for regenerative medicine. Moreover, we are investigating the direct effects of diabetes and diabetes-related drugs on crdiovascular health including human stem cell-derived cardiomyocyte organoid models.